Overview

A Phase 3, Randomized, Double-Blind Study to Assess the Efficacy of Difamilast Ointment in Mild to Moderate AD

Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase 3 Double Blind multi-center study conducted at 40 US investigational sites to assess the efficacy and safety of Difamilast Ointment 1% in subjects ≥2 years of age with mild to moderate atopic dermatitis.
Phase:
Phase 3
Details
Lead Sponsor:
Acrotech Biopharma Inc.